ReviewTranslational lung cancer research2017
The clinical utility of circulating tumour cells in patients with small cell lung cancer.
Review in Translational lung cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Integrating molecular subtypes, genomics and functional dependencies to identify context-specific therapeutic vulnerabilities in small cell lung cancer.Biomarker research · 2026Review
- Review
- Clinical and translational roles of circulating tumor cells in non-small cell and small cell lung cancer: a narrative review.Journal of thoracic disease · 2026Review
- Integrative analysis of circulating tumor cells (CTCs) and exosomes from small-cell lung cancer (SCLC) patients: a comprehensive approach.Molecular oncology · 2025Article
- Current and future therapies for small cell lung carcinoma.Journal of hematology & oncology · 2025Review
- State of the art in treatment of small cell lung cancer.Therapeutic advances in medical oncology · 2025Review
- Circulation of rare events in the liquid biopsy for early detection of lung mass lesions.Thoracic cancer · 2024Article
- Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer.JCO precision oncology · 2024Article
- Circulating Tumor Cells: From Basic to Translational Research.Clinical chemistry · 2024Review
- Circulating tumor cell-derived preclinical models: current status and future perspectives.Cell death & disease · 2023Review
- Plasticity of circulating tumor cells in small cell lung cancer.Scientific reports · 2023Article
- SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023Review
- Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade.British journal of cancer · 2022Review
- Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Circulating tumor cell profiling for precision oncology.Molecular oncology · 2021Review
- Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation.Cancers · 2021Review
- Review
- Exploration of Circulating Tumour Cell (CTC) Biology: A Paradigm Shift in Liquid Biopsy.Indian journal of clinical biochemistry : IJCB · 2021Review
- Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer.Biomedicines · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Small cell lung cancer (SCLC) accounts for 15% of lung cancer diagnosed worldwide. It is aggressive and characterised by early metastatic spread with rapid development of chemo resistance such that less than 5% of patients diagnosed survive 5 years. Surgery is rarely performed and failure to identify new effective treatments has been attributed in a large part to lack of good quality tumour biopsies available for translational research. Liquid biopsies provide a minimally invasive alternative to traditional tumour biopsy. Circulating tumour cells (CTCs) are abundant in SCLC and can be enriched and isolated from a venous blood sample. In recent years progress has been made into the molecular characterisation of CTCs and their use to form tumour xenografts in mice for preclinical studies. This review will discuss the current status of the clinical utility of CTCs in patients with SCLC, highlighting their potential application to treatment decision making, drug development in clinical trials and preclinical testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.